Role of daunorubicinol in daunorubicin-induced cardiotoxicity as evaluated with the model of isolated perfused rat heart

Pharmacology and Toxicology

Volumn 88, Issue 5, 2001, Pages 250-254

  Platel, Denis ^a   Bonoron Adèle, Simone ^b   Robert, Jacques ^a  

^a INSTITUT BERGONIÉ   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DAUNORUBICIN; DAUNORUBICINOL; DOXORUBICIN; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG ACCUMULATION; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE PRESSURE; HEART LEFT VENTRICLE RELAXATION; HEART PERFUSION; ISOLATED HEART; MALE; METABOLITE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0035023145     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0773.2001.d01-112.x     Document Type: Article

References (17)

1. Baurain, R., D. Deprez-De Campeneere & A. Trouet: Rapid determination of doxorubicin and its fluorescent metabolites by high-pressure liquid chromatography. Anal. Biochem. 1979, 94, 112-116.
2. Cusack, B. J., P. S. Mushlin, L. D. Voulelis, X. D. Li, R. J. Boucek & R. D. Olson: Daunorubicin-induced cardiac injury in the rabbit -a role for daunorubicinol? Toxicol. Appl. Pharmacol. 1993, 118, 177-185.
3. Danesi, R., M. Del Tacca, C. Bernardini & S. Penco: Exogenous doxorubicinol induces cardiotoxic effects in rats. Eur. J. Cancer Clin. Oncol. 1987, 23, 907-913.
4. Felsted, R. L., D. R. Richter & N. R. Bachur: Rat liver aldehyde reductase. Biochem. Pharmacol. 1977, 26, 1117-1124.
5. Forrest, G. L., B. Gonzales & H. Rivera: Daunorubicin-induced cardiotoxicity is decreased in transgenic mice with heart-specific expression of human carbonyl reductase. Proc. Amer. Assoc. Cancer Res. 1998, 39, 597 (Abstract #4060).
6. Forrest, G. L., B. Gonzales & W. Tseng: Doxorubicin-induced cardiotoxicity increases in transgenic mice expressing heart-specific of human carbonyl reductase. Proc. Amer. Assoc. Cancer Res. 1999, 40, 387 (Abstract #2560).
7. Harrington, K. J., C. R. Lewanski & G. S. Stewart: Liposomes as vehicles for targeted therapy of cancer. 2. Clinical development. Clin. Oncol. 2000, 12, 16-24.
8. Lorell, B. H., L. F. Wewler, S. Momomura, E. Weinberg & C. S. Apstein: The influence of pressure overload left ventricular hypertrophy on diastolic properties during hypoxia in isovolumically contracting rat hearts. Circ. Res. 1986, 58, 653-663.
9. Loveless, H., E. Arena, R. L. Felsted & N. R. Bachur: Comparative mammalian metabolism of adriamycin and daunorubicin. Cancer Res. 1978, 38, 593-598.
10. Minotti, G., G. Cairo & E. Monti: Role of iron in anthracycline cardiotoxicity: new tunes for an old song? FASEB J. 1999, 13, 199-212.
11. Olson, R. D., P. S. Mushlin, D. E. Brenner, S. Fleischer, B. J. Cusack, B. K. Chang & R. J. Boucek: Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc. Nat. Acad. Sci. USA 1988, 85, 3585-3589.
12. Platel, D., P. Pouna, S. Bonoron-Adèle & J. Robert: Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model. Anti-Cancer Drug 1999a, 10, 671-676.
13. Platel, D., S. Bonoron-Adèle, R. K. Dix & J. Robert: Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin. Brit. J. Cancer 1999b, 81, 24-27.
14. Platel, D., P. Pouna, S. Bonoron-Adèle & J. Robert: Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart. Toxicol. Appl. Pharmacol. 2000, 163, 135-140.
15. Pouna, P., S. Bonoron-Adèle, G. Gouverneur, L. Tariosse, P. Besse & J. Robert: Evaluation of anthracycline cardiotoxicity with the isolated perfused rat heart: comparison of new analogues to doxorubicin. Cancer Chemother, Pharmacol. 1995, 35, 257-261.
16. Pouna, P., S. Bonoron-Adèle, G. Gouverneur, L. Tariosse, P. Besse & J. Robert: Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Brit. J. Pharmacol. 1996, 117, 1593-1599.
17. Robert, J. & L. Gianni: Pharmacokinetics and metabolism of anthracyclines. Cancer Surv. 1993, 17, 219-252.